Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  2. PHAT

(PHAT)

NMS – Real Time Price. Currency in USD

10.58

-0.21 (-1.95%)

At close: Mar 27, 2026, 4:00 PM EDT

10.58

0.00 (0.00%)

After-hours: Mar 27, 2026, 4:34 PM EDT

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile
Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target
27.03.2026

Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target

Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to Overweight from Equal Weight on Friday, raising her price target to $18 from $16.

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
11.03.2026

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript
26.02.2026

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates
26.02.2026

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.79 per share a year ago.

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
26.02.2026

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating expenses of $55.9 million; non-GAAP operating expenses of $50.3 million and net cash usage of approximately $5.2 million, reflecting continued expense discipline Strengthened financial position through $130 million equity offering and modification of term debt Providing FY 2026 guidance; operating profitability expected beginning in Q3 2026 and for FY 2026 Management to host conference call today, February 26, 2026, at 8:00 a.m. EST FLORHAM PARK, N.J.

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
23.02.2026

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference in Boston, MA Date: Monday, March 2, 2026Company Presentation: 10:30 am EST Management to participate in one-on-one meetings throughout the conference Jefferies Biotech on the Beach Summit in Miami, FL Date: Tuesday, March 10, 2026 Management to participate in one-on-one meetings throughout the conference Barclays 28th Annual Global Healthcare Conference in Miami, FL Date: Wednesday, March 11, 2026Fireside Chat: 3:30 pm EDT Management to participate in one-on-one meetings throughout the conference To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations.

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
17.02.2026

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EST on Thursday, February 26, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update.

Videos

No Data

There is no data to display

Press releases

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
26.02.2026

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating expenses of $55.9 million; non-GAAP operating expenses of $50.3 million and net cash usage of approximately $5.2 million, reflecting continued expense discipline Strengthened financial position through $130 million equity offering and modification of term debt Providing FY 2026 guidance; operating profitability expected beginning in Q3 2026 and for FY 2026 Management to host conference call today, February 26, 2026, at 8:00 a.m. EST FLORHAM PARK, N.J.

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
08.01.2026

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the pricing of an underwritten public offering of 6,875,000 shares of its common stock and pre-funded warrants to purchase 1,250,078 shares of common stock.

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
07.01.2026

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering.

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
07.01.2026

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced certain preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. Preliminary Fourth Quarter 2025 Financial Results